Dementia affects tens of millions of people around the world and is becoming more common as life expectancy increases.
The condition causes a gradual decline in memory, thinking, language, emotional control, and everyday functioning. Patients may eventually struggle with communication, decision-making, movement, and recognizing people or places.
The growing number of dementia cases has created enormous challenges for healthcare systems and families. Scientists estimate that more than 57 million people currently live with dementia globally, and that number could nearly double within the next 20 years.
Although Alzheimer’s disease is the most common form of dementia, it is not the only one. Many different brain diseases can lead to dementia symptoms, and some are much harder to diagnose accurately.
One of these disorders is frontotemporal lobar degeneration, known as FTLD. This disease mainly damages the frontal and temporal regions of the brain, areas involved in behavior, emotions, speech, and personality.
Unlike Alzheimer’s disease, memory loss may not appear first in FTLD patients. Instead, people may develop emotional instability, personality changes, impulsive behavior, language difficulties, or social problems. Because these symptoms can resemble psychiatric illnesses, diagnosis is often difficult.
Doctors currently rely on brain scans, cognitive testing, and patient symptoms to evaluate FTLD. However, these tools cannot always determine the exact molecular changes occurring inside the brain.
Researchers have therefore been searching for biomarkers that can identify the disease more accurately.
Now, scientists from Mass General Brigham have developed an ultrasensitive test that may help doctors detect a specific subtype of FTLD more precisely.
The findings were published in the scientific journal Alzheimer’s & Dementia.
The new test focuses on a protein called TDP-43. In healthy cells, TDP-43 helps regulate important cellular functions. However, in some neurodegenerative diseases, the protein becomes abnormal, folds incorrectly, and forms toxic clumps inside brain cells.
These abnormal TDP-43 clumps are strongly linked to a subtype of FTLD known as FTLD-TDP.
Researchers say identifying this disease while patients are alive has been extremely challenging because there have been no reliable biomarker tests available.
The scientists adapted technology they had previously used to study Parkinson’s disease. Earlier work had focused on detecting abnormal alpha-synuclein proteins, which are associated with Parkinson’s disease and related disorders.
Using similar principles, the team created what they call a digital seed amplification assay, or dSAA, to detect abnormal TDP-43 protein seeds.
The test examines cerebrospinal fluid, the clear liquid surrounding the brain and spinal cord. Cerebrospinal fluid often contains important biological signals related to brain disease.
Researchers divided tiny amounts of this fluid into microscopic compartments and used advanced imaging techniques to count the number of abnormal TDP-43 protein seeds present in each sample.
The study included cerebrospinal fluid samples from 30 individuals believed to have FTLD-TDP and 10 healthy controls.
The results showed clear differences between the two groups. Patients with FTLD-TDP had much higher concentrations of abnormal TDP-43 seeds compared with healthy individuals.
The researchers also found that patients with more severe symptoms tended to have higher seed levels. This suggests the test may reflect disease activity and progression, not just disease presence.
Scientists believe this could become extremely valuable for future research and treatment development.
One of the biggest problems in dementia research is that many diseases produce similar outward symptoms even though the underlying brain damage is very different. Two patients may both show confusion or personality changes while actually having completely different molecular diseases.
Without accurate diagnosis, researchers may struggle to test medications properly because clinical trials may include patients with mixed disease types.
A reliable biomarker for FTLD-TDP could therefore improve patient selection for clinical trials and increase the chances of discovering effective treatments.
The researchers also hope the test could one day help monitor whether experimental drugs are successfully slowing disease progression.
Dr. Andrew M. Stern from the Mass General Brigham Neuroscience Institute explained that much more work is still needed before the test can be used routinely in medical practice. However, he said the study creates an important framework for future development of diagnostic tools for FTLD.
The scientists acknowledged several important limitations in the research.
The study involved a relatively small number of participants, and diagnoses were not confirmed through brain autopsy, which remains the gold standard for identifying neurodegenerative disease.
The researchers also did not compare the FTLD-TDP group with patients who had Alzheimer’s disease or other dementias, so more research is needed to determine how specifically the test distinguishes FTLD-TDP from other disorders.
Future studies will likely involve larger patient populations, long-term follow-up, and comparison with multiple forms of neurodegenerative disease.
Despite these limitations, experts say the findings are encouraging because reliable biomarkers for rare dementias are urgently needed.
The research also highlights how rapidly dementia science is advancing. Scientists are increasingly focusing on the molecular causes of disease rather than relying only on symptoms or brain scans. This molecular approach may eventually lead to earlier diagnosis, better monitoring, and more personalized treatments.
If you care about dementia, please read studies that eating apples and tea could keep dementia at bay, and Olive oil: a daily dose for better brain health.
For more health information, please see recent studies what you eat together may affect your dementia risk, and time-restricted eating: a simple way to fight aging and cancer.
The study was published in Alzheimer’s & Dementia by researchers from Mass General Brigham.
Source: Mass General Brigham.
